vs
Side-by-side financial comparison of LivaNova PLC (LIVN) and STONERIDGE INC (SRI). Click either name above to swap in a different company.
LivaNova PLC is the larger business by last-quarter revenue ($360.9M vs $205.2M, roughly 1.8× STONERIDGE INC). On growth, LivaNova PLC posted the faster year-over-year revenue change (12.1% vs -6.0%). LivaNova PLC produced more free cash flow last quarter ($50.2M vs $2.6M). Over the past eight quarters, LivaNova PLC's revenue compounded faster (10.6% CAGR vs -7.4%).
LivaNova, plc is an American medical device manufacturer based in the UK. The company develops devices used for cardiac surgery and neuromodulation. The company was formed in 2015 by a $2.7B merger between Houston, Texas-based Cyberonics, Inc. and Milan, Italy-based Sorin S.p.a. The company trades on the NASDAQ stock exchange under the ticker symbol "LIVN".
Stoneridge Inc is a global designer and manufacturer of advanced electrical and electronic components, integrated systems, and sensor solutions. It serves automotive, commercial vehicle, off-highway, and aerospace sectors, delivering products that boost vehicle safety, efficiency, connectivity, and environmental performance across key global markets.
LIVN vs SRI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $360.9M | $205.2M |
| Net Profit | $30.9M | — |
| Gross Margin | 65.2% | 16.2% |
| Operating Margin | 11.8% | -14.4% |
| Net Margin | 8.6% | — |
| Revenue YoY | 12.1% | -6.0% |
| Net Profit YoY | -44.7% | — |
| EPS (diluted) | $0.57 | $-2.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $360.9M | $205.2M | ||
| Q3 25 | $357.8M | $210.3M | ||
| Q2 25 | $352.5M | $228.0M | ||
| Q1 25 | $316.9M | $217.9M | ||
| Q4 24 | $321.8M | $218.2M | ||
| Q3 24 | $318.1M | $213.8M | ||
| Q2 24 | $318.6M | $237.1M | ||
| Q1 24 | $294.9M | $239.2M |
| Q4 25 | $30.9M | — | ||
| Q3 25 | $26.8M | $-9.4M | ||
| Q2 25 | $27.2M | $-9.4M | ||
| Q1 25 | $-327.3M | $-7.2M | ||
| Q4 24 | $55.9M | — | ||
| Q3 24 | $33.0M | $-7.1M | ||
| Q2 24 | $16.3M | $2.8M | ||
| Q1 24 | $-41.9M | $-6.1M |
| Q4 25 | 65.2% | 16.2% | ||
| Q3 25 | 68.4% | 20.3% | ||
| Q2 25 | 67.8% | 21.5% | ||
| Q1 25 | 69.7% | 21.2% | ||
| Q4 24 | 68.2% | 19.5% | ||
| Q3 24 | 70.8% | 20.8% | ||
| Q2 24 | 68.7% | 22.7% | ||
| Q1 24 | 70.3% | 20.2% |
| Q4 25 | 11.8% | -14.4% | ||
| Q3 25 | 15.1% | -1.6% | ||
| Q2 25 | 15.4% | -1.1% | ||
| Q1 25 | 15.3% | -1.5% | ||
| Q4 24 | 11.5% | -2.0% | ||
| Q3 24 | 11.2% | 0.1% | ||
| Q2 24 | 12.6% | 1.4% | ||
| Q1 24 | 5.5% | 0.1% |
| Q4 25 | 8.6% | — | ||
| Q3 25 | 7.5% | -4.5% | ||
| Q2 25 | 7.7% | -4.1% | ||
| Q1 25 | -103.3% | -3.3% | ||
| Q4 24 | 17.4% | — | ||
| Q3 24 | 10.4% | -3.3% | ||
| Q2 24 | 5.1% | 1.2% | ||
| Q1 24 | -14.2% | -2.6% |
| Q4 25 | $0.57 | $-2.76 | ||
| Q3 25 | $0.49 | $-0.34 | ||
| Q2 25 | $0.50 | $-0.34 | ||
| Q1 25 | $-6.01 | $-0.26 | ||
| Q4 24 | $1.04 | $-0.22 | ||
| Q3 24 | $0.60 | $-0.26 | ||
| Q2 24 | $0.30 | $0.10 | ||
| Q1 24 | $-0.78 | $-0.22 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $635.6M | $66.3M |
| Total DebtLower is stronger | $376.1M | $180.9M |
| Stockholders' EquityBook value | $1.2B | $179.8M |
| Total Assets | $2.6B | $551.2M |
| Debt / EquityLower = less leverage | 0.31× | 1.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $635.6M | $66.3M | ||
| Q3 25 | $646.1M | $54.0M | ||
| Q2 25 | $593.6M | $49.8M | ||
| Q1 25 | $738.4M | $79.1M | ||
| Q4 24 | $428.9M | $71.8M | ||
| Q3 24 | $346.4M | $54.1M | ||
| Q2 24 | $329.2M | $42.1M | ||
| Q1 24 | $309.2M | $48.4M |
| Q4 25 | $376.1M | $180.9M | ||
| Q3 25 | $434.5M | — | ||
| Q2 25 | $430.6M | — | ||
| Q1 25 | $628.2M | — | ||
| Q4 24 | $627.0M | $201.6M | ||
| Q3 24 | $625.5M | — | ||
| Q2 24 | $624.5M | — | ||
| Q1 24 | $623.8M | — |
| Q4 25 | $1.2B | $179.8M | ||
| Q3 25 | $1.2B | $251.2M | ||
| Q2 25 | $1.1B | $260.5M | ||
| Q1 25 | $1.0B | $253.1M | ||
| Q4 24 | $1.3B | $245.3M | ||
| Q3 24 | $1.3B | $271.4M | ||
| Q2 24 | $1.2B | $270.5M | ||
| Q1 24 | $1.2B | $277.3M |
| Q4 25 | $2.6B | $551.2M | ||
| Q3 25 | $2.6B | $632.1M | ||
| Q2 25 | $2.5B | $639.4M | ||
| Q1 25 | $2.6B | $657.4M | ||
| Q4 24 | $2.5B | $621.6M | ||
| Q3 24 | $2.5B | $662.5M | ||
| Q2 24 | $2.5B | $666.7M | ||
| Q1 24 | $2.5B | $675.4M |
| Q4 25 | 0.31× | 1.01× | ||
| Q3 25 | 0.38× | — | ||
| Q2 25 | 0.38× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | 0.47× | 0.82× | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 0.50× | — | ||
| Q1 24 | 0.51× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $82.4M | $8.8M |
| Free Cash FlowOCF − Capex | $50.2M | $2.6M |
| FCF MarginFCF / Revenue | 13.9% | 1.3% |
| Capex IntensityCapex / Revenue | 8.9% | 3.0% |
| Cash ConversionOCF / Net Profit | 2.67× | — |
| TTM Free Cash FlowTrailing 4 quarters | $173.3M | $12.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $82.4M | $8.8M | ||
| Q3 25 | $85.1M | $3.6M | ||
| Q2 25 | $62.9M | $10.7M | ||
| Q1 25 | $24.0M | $10.9M | ||
| Q4 24 | $78.7M | $19.2M | ||
| Q3 24 | $51.0M | $10.8M | ||
| Q2 24 | $43.4M | $8.7M | ||
| Q1 24 | $10.0M | $9.1M |
| Q4 25 | $50.2M | $2.6M | ||
| Q3 25 | $62.2M | $-2.7M | ||
| Q2 25 | $47.8M | $7.4M | ||
| Q1 25 | $13.2M | $4.8M | ||
| Q4 24 | $68.3M | $14.0M | ||
| Q3 24 | $32.8M | $4.6M | ||
| Q2 24 | $31.2M | $1.5M | ||
| Q1 24 | $3.6M | $3.3M |
| Q4 25 | 13.9% | 1.3% | ||
| Q3 25 | 17.4% | -1.3% | ||
| Q2 25 | 13.6% | 3.3% | ||
| Q1 25 | 4.2% | 2.2% | ||
| Q4 24 | 21.2% | 6.4% | ||
| Q3 24 | 10.3% | 2.2% | ||
| Q2 24 | 9.8% | 0.6% | ||
| Q1 24 | 1.2% | 1.4% |
| Q4 25 | 8.9% | 3.0% | ||
| Q3 25 | 6.4% | 3.0% | ||
| Q2 25 | 4.3% | 1.4% | ||
| Q1 25 | 3.4% | 2.8% | ||
| Q4 24 | 3.2% | 2.4% | ||
| Q3 24 | 5.7% | 2.9% | ||
| Q2 24 | 3.8% | 3.0% | ||
| Q1 24 | 2.2% | 2.4% |
| Q4 25 | 2.67× | — | ||
| Q3 25 | 3.18× | — | ||
| Q2 25 | 2.32× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.41× | — | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 2.65× | 3.11× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
SRI
| Control Devices | $51.7M | 25% |
| Electronics | $38.0M | 19% |
| EE | $34.2M | 17% |
| SE | $28.6M | 14% |
| NL | $24.5M | 12% |
| Stoneridge Brazil | $14.1M | 7% |
| Asia Pacific | $13.1M | 6% |
